Intellia Therapeutics (NTLA): Price/Earnings to Growth Ratio
Intellia Therapeutics (NTLA) outsources its drug production, relying on external contractors. The level of undervaluation based on the PEG ratio is clearly demonstrated by the current trend, where the value of 0.00 expresses the metric's level. Meanwhile, the patent protection of CRISPR therapy creates a significant market barrier, and strategic scientific alliances with biotech partners accelerate the development of innovative treatments for genetic pathologies.
Intellia Therapeutics (NTLA) - metric breakdowns and financial figures
- current quotes and average value forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Intellia Therapeutics|NTLA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital intelliatx.com|NTLA - Company Total Debt|Debt to Book Capital Intellia|NTLA - Company Long-Term Debts|Company Short-Term Loans and Borrowings Intellia Therapeutics|Immediate Liquidity intelliatx.com
- financial results and valuation multiples details:
NTLA - Company Net Income|Expected Net Income Intellia Therapeutics|NTLA - P/E Multiple|Forward P/E Multiple Intellia Corp|NTLA - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Intellia|NTLA - Operating profit EBITDA|Net earnings per one share for the last twelve months Intellia Therapeutics|NTLA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth intelliatx.com|NTLA - Net earnings per share growth this year|Projected earnings per share increase next year Intellia Therapeutics
- issuer revenue and sales details:
Summary company analytics:Intellia Therapeutics Inc
The PEG ratio compares the P/E multiple with earnings growth rates, determining whether the current share price is justified by the business's growth dynamics. For Intellia Therapeutics (NTLA), which develops CRISPR technologies, this growth company undervaluation metric helps assess the efficiency of investments in proprietary genome editing platforms relative to their capitalization potential.
Competing companies
TEM - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Qiagen Group QGEN|Isis Pharmaceuticals - Price/Earnings to Growth Ratio|RGEN - Price/Earnings to Growth Ratio|RNA: Price/Earnings to Growth Ratio|CRSP: PEG Multiple|WGS - Growth-Adjusted Market Cap to Net Income|RARE (Ultragenyx Pharma) - PEG Multiple|PEG Multiple Beam Tx|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST (twistbioscience.com) - Growth-Adjusted Payback Ratio|10x Genomics - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio STOK (Stoke Therapeutics Inc)|BioLife Corp - PEG Multiple|Growth-Adjusted Payback Ratio WVE (Wave Pharma)|MAZE: PEG Multiple|Price to Earnings Adjusted for Growth Rate sionnatx.com (SION)|Price/Earnings to Growth Ratio Prime Medicine|TSHA: Growth-Adjusted Payback Ratio|PEG Multiple QURE|PEG Multiple MeiraGTx Corp (MGTX)|Price/Earnings to Growth Ratio REGENXBIO Inc. RGNX|SLDB (solidbio.com) - Market Cap to Earnings and Growth Ratio|Ocugen - PEG Multiple|Price to Earnings Adjusted for Growth Rate Pacific Biosciences of California, Inc.|BNTC (Benitec) - Price/Earnings to Growth Multiple|Design Corp (DSGN) - PEG Multiple|Price/Earnings to Growth Multiple RCKT|FDMT (4dmoleculartherapeutics.com) - Company Value to Earnings Growth Ratio|PEG Multiple LXEO|Growth-Adjusted Market Cap to Net Income korrobio.com|PEG Multiple EDIT (Editas)|SLN - Price/Earnings to Growth Multiple|PRQR - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Codexis, Inc. CDXS|Sangamo Therapeutics, Inc. (SGMO) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio NAUT|Price/Earnings to Growth Multiple MGX|DTIL (Precision BioSciences Inc.) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Generation Bio Co. (GBIO)|Price/Earnings to Growth Ratio BOLD (boundlessbio.com)|PEG Multiple XCUR (Exicure)|PEG Multiple Imunon Inc IMNN|RXi Pharmaceuticals - PEG Multiple|MBIO (Mustang Bio, Inc.) - Growth-Adjusted P/E Ratio|transcodetherapeutics.com (RNAZ) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio BNGO|APDN (Applied DNA Sciences, Inc.) - PEG Multiple|PEG Multiple bluebird bio Inc.|PEG Multiple IPA|Growth-Adjusted Market Cap to Net Income Omega Therapeutics Corp|Price/Earnings to Growth Ratio Singular Genomics Systems OMIC|RGLS: Growth-Adjusted P/E Ratio|SYRS: Price/Earnings to Growth Multiple|Telesis Bio Inc. - Company Value to Earnings Growth Ratio|TCON: PEG Multiple|Price to Earnings Adjusted for Growth Rate Unity Biotechnology, Inc (UBX)
